Evidence map›Paper›PMID 41850490›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026

Selective impact on regulatory T cells with sustained functional phenotypes by the interleukin-2 mutein VIS171 in a nonhuman primate model.

Davide Schiliró, Matt Tunbridge, Nolan J Brown, Joshua Lopez, Tammy Tollison, Ethan Smith, Joseph Ladowski, Alessandro Martinino, Meghan Hu, Allison Schwalb and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Davide SchiliróDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Matt TunbridgeDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Nolan J BrownLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Joshua LopezLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Tammy TollisonDepartment of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, USA.
Ethan SmithDepartment of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, USA; Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA.
Joseph LadowskiDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Alessandro MartininoDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Meghan HuDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Allison SchwalbDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Janghoon YoonDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Rafaela BelloniDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
John J O'NeilVisterra Inc, Waltham, Massachusetts, USA.
Luke N RobinsonVisterra Inc, Waltham, Massachusetts, USA.
Asher D SchachterVisterra Inc, Waltham, Massachusetts, USA.
Gregory J BabcockVisterra Inc, Waltham, Massachusetts, USA.
David OldachVisterra Inc, Waltham, Massachusetts, USA.
Xinxia PengDepartment of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, USA; Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA.
Hokyung Kay ChungLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address: hkchung@unc.edu.
Stuart KnechtleDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. Electronic address: stuart.knechtle@duke.edu.
Jean KwunDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. Electronic address: jean.kwun@duke.edu.

Funding

The Risks and Opportunities of Homeostatic RepopulationU19AI131471 · NIAID · DUKE UNIVERSITY · PI Stuart Johnston Knechtle · 2017 to 2026
$30.4M
Next-generation T cell therapy: SMARTER T cells for enhanced and durable anti-tumor immunityK01EB034321 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hokyung Kay Chung · 2023 to 2026
$639k
NIAID NIH HHS U19 AI131471NIBIB NIH HHS K01 EB034321
6 · The paper itself

Abstract

The interleukin-2 mutein, VIS171, was engineered to extend half-life and enhance selective binding and expansion of regulatory T cells (Tregs) expressing high levels of the trimeric interleukin-2 receptor. This study evaluated the effects of VIS171 on immune cell populations in nonhuman primates, focusing on its ability to selectively expand Tregs, and then characterized their phenotype during expansion and contraction. Naïve rhesus macaques were treated subcutaneously with VIS171, along with daily rapamycin. VIS171 was well tolerated with repeated administration. Tregs, identified as cluster of differentiation CD4

Indexed as

Interleukin-2T-Lymphocytes, RegulatoryAnimalsCell ProliferationMacaca mulattaMalePhenotypeSirolimusInterleukin-2SirolimusIL-2 muteininterleukin-2kidney transplantationregulatory T cellstoleranceVIS171

Identifiers

PMID41850490
PMCPMC13158889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.